𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Malignant paraganglioma caused by a novel germline mutation of the succinate dehydrogenase D-gene—A case report

✍ Scribed by Konstantinos Papaspyrou; Heidi Rossmann; Christian Fottner; Matthias M. Weber; Wolf Mann; Karl J. Lackner; Kai Helling

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
353 KB
Volume
30
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Paragangliomas of the head and neck are rare, mostly benign tumors. Approximately 10% to 15% of paragangliomas are caused by mutations in the succinate dehydrogenase (SDH) genes B, C, or D. These are often multifocal as part of paraganglioma syndromes and hormone secreting, and malignant particularly associated with mutations in SDHB.

Methods and Results

A 29‐year‐old man was seen with recurrent paraganglioma. The patient's father reportedly suffered from bilateral carotid body tumors. Imaging studies showed metastases in both lungs and the liver. There was no increased hormone production by the tumor. Sequence analysis of the SDH genes revealed a novel C to T nonsense mutation in the first exon of the SDHD gene (R17X).

Conclusions

A novel mutation in the SDHD gene associated with malignant paraganglioma is reported. This case underscores the relevance of family history and genetic analysis, thus permitting early detection of unaffected carriers. These have to be monitored clinically, biochemically and by imaging techniques. © 2008 Wiley Periodicals, Inc. Head Neck, 2008

📜 SIMILAR VOLUMES

Mutational spectrum of the succinate sem
Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency
✍ Shinjiro Akaboshi; Boris M. Hogema; Andrea Novelletto; Patrizia Malaspina; Gajja 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

Succinate semialdehyde dehydrogenase (SSADH; ALDH5A1) deficiency, a rare metabolic disorder that disrupts the normal degradation of GABA, gives rise to a highly heterogeneous neurological phenotype ranging from mild to very severe. The nature of the mutation has so far been reported in patients from